-
PURE Bioscience Announces GRAS Determination for SDC as a Contact Biocide in Food Processing
Thursday, July 7, 2011 - 7:05am | 221PURE Bioscience, Inc. (NASDAQ: PURE) today announced that it has completed the first Generally Recognized as Safe self-affirmation for SDC when used on food processing equipment, machinery and utensils. A committee of independent experts critically reviewed efficacy and toxicity data for SDC and...
-
Rodman & Renshaw Reiterates Market Outperform and PT of $7 on Enzo Biochem
Thursday, July 7, 2011 - 5:57am | 49Rodman & Renshaw reiterated its Market Outperform rating on Enzo Biochem (NYSE: ENZ). At the same time, the rating agency left its price target on the company's stock unchanged at $7. On Wednesday, Enzo added 4.31% to its value to end the day at $4.60.
-
Affymetrix Sees Q2 Revenue of $64-65M vs. $74.08M Est
Wednesday, July 6, 2011 - 4:05pm | 84Affymetrix, Inc. (Nasdaq: AFFX) today reported that based on preliminary financial data, the Company expects total revenue for the second quarter of 2011 to be in the range of $64-65 million. The Company expects product revenue for the second quarter of 2011 to be approximately $58-59 million,...
-
Cambrex and Tillotts Enter a Development and Commercialization Agreement for Proprietary 5-ASA-Based Technology
Wednesday, July 6, 2011 - 8:49am | 43Cambrex Corporation (NYSE: CBM) and Tillotts Pharma AG are pleased to announce they have entered into a Development and Commercialization Agreement for a proprietary mesalamine-based technology for use in the treatment of Inflammatory Bowel Disease.
-
Enzo Scientists Report on Key Discovery of Novel Targets for Metabolic Bone Disease and Other Conditions
Wednesday, July 6, 2011 - 8:04am | 259Enzo Biochem Inc. (NYSE: ENZ) today reported that scientists from its Enzo Therapeutics group presented a podium session entitled “The Presence of Sulfated Tyrosine In Scelerostin and Dkk1 Ligands and its Effect on Wnt Signaling” at the WNT 2011 conference in Los Angeles Thursday, June 30, 2011...
-
Rodman & Renshaw Reiterates BioDelivery Sciences Market Outperform, $5.50 PT
Friday, July 1, 2011 - 12:00pm | 73Rodman & Renshaw reiterated its BioDelivery Sciences (NASDAQ: BDSI) Market Outperform rating and $5.50 price target in a research report published today. In the report, Rodman & Renshaw states, "As we've noted since in our August 2010 initiation, we find more value in BDSI's pipeline than...
-
Harvard Bioscience, Inc. Acquires CMA Microdialysis' Preclinical Business
Friday, July 1, 2011 - 9:02am | 131Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it has acquired the preclinical business unit of CMA Microdialysis AB through a purchase of assets. CMA Microdialysis AB is a privately held Swedish manufacturer of microdialysis products. Founded in 1984, the company pioneered the...
-
Stocks to Watch for 07/1/11: Fresh 52 Week Highs and Lows
Friday, July 1, 2011 - 4:16am | 2869Stocks trading at or near 52-week highs and lows provide excellent trading opportunities, as volatility tends to increase at such levels. The following stocks hit new 52-week highs in Thursday's trading session: 1) Walter Investment Company (NYSE: WAC): Shares of Walter Investment hit a 52-week...
-
Mad Money Lightning Round: Cramer Advises Investors To Buy Illumina
Thursday, June 30, 2011 - 1:09am | 338On CNBC's Mad Money, Jim Cramer said during the Lightning Round that Hudson City Bancorp (NASDAQ: HCBK) "turned out to be far more controversial than I realized ... If you want a good regional, I suggest First Niagara Financial (NASDAQ: FNFG)." For Transocean (NYSE: RIG), he said, "I like it, a...
-
Stocks to Watch for 6/29/11: Fresh 52 Week Highs and Lows
Wednesday, June 29, 2011 - 4:11am | 2861Stocks trading at or near 52-week highs and lows provide excellent trading opportunities, as volatility tends to increase at such levels. The following stocks hit new 52-week highs in Tuesday's trading session: 1) CIGNA (NYSE: CI): Shares of CIGNA hit a 52-week high of $51.16 in Tuesday's...
-
Illumina Brings Down Cost Of DNA Analysis
Tuesday, June 28, 2011 - 2:17pm | 74The new frontier of genetic analysis is developing so fast that industry leader Illumina plans to come out with an iPad app. Some of Illumina's (ILMN) software used in gene sequencing already runs in the Internet cloud. Illumina showed off its new "MiGenome" iPad app at the third annual Consumer...
-
AMRI and Proteros Biostructures GmbH Announce Strategic Alliance
Tuesday, June 28, 2011 - 8:05am | 64AMRI (Nasdaq: AMRI) and Proteros Biostructures GmbH announced today that they have signed an agreement for a joint offering to the life sciences industry. Proteros, an expert in the field of protein crystallization and X-ray structural analysis, provides services that complement AMRI's existing...
-
Oppenheimer Reiterates Outperform on WuXi PharmaTech and ShangPharma
Monday, June 27, 2011 - 7:48am | 43Oppenheimer reiterated its Outperform rating on WuXi PharmaTech (NYSE: WX) and ShangPharma (NYSE: SHP). On Friday, WuXi finished the day at $16.05, while ShangPharma close the day at $10.
-
Goldman Sachs Updates Illumina Estimates
Friday, June 24, 2011 - 7:37am | 64Goldman Sachs is updating its Illumina Inc. (NASDAQ: ILMN) estimates to reflect “our latest sequencing system placement assumptions for both HiSeq and MiSeq for 2011-2014.” “We now believe the mix will shift more towards MiSeq than HiSeq and as a result our 2011-2013 EPS estimates go to $1.55, $2....
-
MSMB Capital Management Proposes Acquisition of SeraCare for $4.25 Per Share
Thursday, June 23, 2011 - 9:46am | 174MSMB Capital Management today announced that it has made a proposal to the Board of Directors of SeraCare Life Sciences, Inc. (NASDAQ: SRLS) to acquire all the outstanding common stock of SeraCare for $4.25 per share or an aggregate of $82 million. This proposal represents an approximate 22%...